AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9214527
Drug: Pramipexole 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 3.0 mg/d
Trial: 9214527
Drug: Pramipexole 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 6.0 mg/d
Trial: 30381621
Drug: Intravenous l-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous l-carnitine
Trial: 30381621
Drug: Intravenous branched-chain
RxNorm normalized name: Machilus thunbergii branch extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous branched-chain amino acids (BCAA)
Trial: 30381621
Drug: Oral l-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral l-carnitine supplementation
Trial: 30381621
Drug: Conventional agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional agents (lactulose and non-absorbable antibiotics)
Trial: 19577936
Drug: metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin plus ADA diet (Met+ADA)
Trial: 12458654
Drug: Candesartan 8
RxNorm normalized name: candesartan 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8 or 16 mg
Trial: 10520057
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) aqueous nasal spray, 200 microg once daily
Trial: 10520057
Drug: Levocabastine (LEV)
DrugBank: Levocabastine (DB01106)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocabastine (LEV) nasal spray, 200 microg twice daily
Trial: 10520057
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) nasal spray
Trial: 8559985
Drug: Misoprostol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (100 mcg intravaginally)
Trial: 1791485
Drug: Enalapril (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (an angiotensin converting enzyme inhibitor)
Trial: 27426699
Drug: CES with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CES with 200 mg caffeine (CAF2)
Trial: 27426699
Drug: CES with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CES with 100 mg caffeine (CAF1)
Trial: 22982471
Drug: Enzogenol® pine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzogenol® pine bark extract (480 mg/day for 6 months)
Trial: 22982471
Drug: Enzogenol® pine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzogenol® pine bark extract (960 mg/day for 5 weeks)
Trial: 22982471
Drug: Enzogenol® pine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzogenol® pine bark extract (single and 14-day repeat dosing in rats and dogs)
Trial: 22982471
Drug: Enzogenol® pine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzogenol® pine bark extract (highest dose level in dogs)
Trial: 18001210
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg purified isoflavones for 12 weeks
Trial: 15533544
Drug: Proactive telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive telephone support with nicotine patches
Trial: 15533544
Drug: Nicotine patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patches (control condition)
Trial: 10213125
Drug: Calcitriol (0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.5mg twice a day)
Trial: 8574714
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole twice daily for 1 week (Phase 1)
Trial: 8574714
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole twice daily for 1 week (Group A)
Trial: 8574714
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole daily for 1 week (Group B)
Trial: 2192985
Drug: CDDP 50
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDDP 50 mg/mq + alizapride
Trial: 2192985
Drug: CDDP 50
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDDP 50 mg/mq + metoclopramide
Trial: 2192985
Drug: CDDP 50
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDDP 50 mg/mq + placebo
Trial: 393299
Drug: Combined preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined preparations containing oestrogen and progestogen
Trial: 29437489
Drug: Daily text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily text message reminders for 30 days
Trial: 30388775
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate and potassium bicarbonate fortified with minerals, ingested twice a day over a nine-day training period.
Trial: 27468541
Drug: Integrated Traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Traditional Chinese Medicine (TCM) with basic treatment
Trial: 22893135
Drug: Hyoscine butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine butylbromide 20 mg
Trial: 16150197
Drug: Naohuandan (NHD),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naohuandan (NHD), 4 capsules each time, 3 times daily for 3 months
Trial: 16150197
Drug: Piracetam, 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam, 1.6 g each time, 3 times daily for 3 months
Trial: 16150197
Drug: High-dosage NHD
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage NHD
Trial: 16150197
Drug: Low-dosage NHD
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage NHD
Trial: 16150197
Drug: Model group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model group (no treatment)
Trial: 12871256
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg once per week for 6 months
Trial: 1619099
Drug: Structural family
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structural family therapy (n = 20)
Trial: 6531953
Drug: Trivalent subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent subunit influenza virus vaccine
Trial: 6531953
Drug: Trivalent split
RxNorm normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent split vaccine
Trial: 22552505
Drug: Short-term antibiotic
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term antibiotic prophylaxis (single dose)
Trial: 22552505
Drug: Long-term antibiotic
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term antibiotic prophylaxis (multiple dose)
Trial: 19414832
Drug: Stent placement
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stent placement and medical treatment (64 patients)
Trial: 19414832
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment only (76 patients)
Trial: 19414832
Drug: Stent placement
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stent placement with medical treatment
Trial: 14971623
Drug: Mainly computer-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly computer-guided self-exposure therapy (FearFighter)
Trial: 14971623
Drug: Entirely clinician-guided
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entirely clinician-guided self-exposure therapy
Trial: 27647820
Drug: Oral cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cannabis
Trial: 27647820
Drug: Inhaled routes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled routes (smoked or vaporized)
Trial: 17803059
Drug: Vazkor 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vazkor 10 mg tablet (test preparation)
Trial: 17803059
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg tablet of the originator product (reference preparation)
Trial: 15217803
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (120 mg vitamin C, 30 mg vitamin E, 6 mg beta carotene, 100 microg selenium, and 20 mg zinc)
Trial: 11427639
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vitamins E and C
Trial: 7981777
Drug: GH 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 0.1 mg/kg/day (n = 10)
Trial: 3057036
Drug: nifedipine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine (120 mg/day)
Trial: 23624215
Drug: Silymarin (420mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (420mg daily)
Trial: 23624215
Drug: Desferrioxamine (40mg/kg/day)
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desferrioxamine (40mg/kg/day) + Silymarin (420mg daily)
Trial: 15550792
Drug: ANP-treated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANP-treated group (n = 13, 0.05 microg/kg/min of synthetic human alpha-ANP administered postoperatively)
Trial: 11075311
Drug: Piroxicam-beta-cyclodextrin (PBCD)
RxNorm normalized name: piroxicam-beta-cyclodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam-beta-cyclodextrin (PBCD) 20 mg
Trial: 11075311
Drug: Piroxicam (Feldene)
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam (Feldene) 20 mg
Trial: 8211041
Drug: Sustained-release bezafibrate
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release bezafibrate 400 mg per day for 56 days
Trial: 30466131
Drug: Alginate therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate therapy (up to 4 times daily for 14 days)
Trial: 26945497
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy with Dermatophagoides pteronyssinus after 2 months of placebo in polysensitized patients.
Trial: 26945497
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy with Dermatophagoides pteronyssinus after 2 months of placebo in monosensitized patients.
Trial: 26945497
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy with Dermatophagoides pteronyssinus in both groups.
Trial: 26945497
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy with Dermatophagoides pteronyssinus in polysensitized patients.
Trial: 20303236
Drug: Fat-free milk
RxNorm normalized name: MILK FAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat-free milk (400 mL daily for mild, 600 mL for moderate, 800 mL for severe constipation)
Trial: 20303236
Drug: Whole milk
RxNorm normalized name: Calcium fortified whole milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole milk (400 mL for 3 days)
Trial: 12085028
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment (injection of epinephrine, mechanical removal of clot, coagulation)
Trial: 8591078
Drug: FAM chemotherapy
RxNorm normalized name: fam-trastuzumab deruxtecan-nxki Injection [Enhertu]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAM chemotherapy (5-FU, doxorubicin, mitomycin C) for 1 year (6 cycles)
Trial: 103722
Drug: Atropine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.5 mg i.v. and 0.5 mg s.c.)
Trial: 103722
Drug: Calcium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium infusion (0.3 mmol/kg.105 min)
Trial: 103722
Drug: Magnesium infusion
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium infusion (0.12 mmol/kg.45 min)
Trial: 21385361
Drug: Pedalling daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pedalling daily for up to ten minutes, for up to ten working days (experimental group)
Trial: 17341317
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol 5 mg after formoterol treatment
Trial: 17341317
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide 40 mug after formoterol treatment
Trial: 17341317
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol 5 mg after placebo treatment
Trial: 17341317
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide 40 mug after placebo treatment
Trial: 14987299
Drug: Heat-inactivated BCG
RxNorm normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-inactivated BCG (0.1 mL injection once a week for 4 weeks)
Trial: 11251566
Drug: 4 weeks
RxNorm normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of terbinafine (62.5 mg daily for <20 kg, 125 mg daily for 20-40 kg, 250 mg daily for >40 kg)
Trial: 11251566
Drug: 8 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of griseofulvin (10 mg/kg daily)
Trial: 3440634
Drug: Piretanide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide (3 to 12 mg daily for 12 weeks)
Trial: 3440634
Drug: Triamterene (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamterene (with and without piretanide) and amiloride in combination with hydrochlorothiazide
Trial: 29168570
Drug: Phleum pratense
RxNorm normalized name: PHLEUM PRATENSE
DrugBank: Phleum pratense pollen (DB10394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phleum pratense subcutaneous immunotherapy (Phl‐SCIT)
Trial: 28654972
Drug: Electronic pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic pill bottles combined with lottery incentives and social support for medication adherence (1003 patients)
Trial: 21621993
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy (15% of MIP) for 6 weeks
Trial: 18959604
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (n = 125)
Trial: 18959604
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (n = 146)
Trial: 10194085
Drug: Lederle/Takeda acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis (DTaP) vaccine
Trial: 10194085
Drug: Lederle whole‐cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lederle whole‐cell component diphtheria and tetanus toxoids and pertussis (DTP) vaccine
Trial: 10194085
Drug: Diphtheria and
RxNorm normalized name: Diphtheria and tetanus vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphtheria and tetanus toxoids (DT) vaccine
Trial: 8546476
Drug: Granisetron hydrochloride
RxNorm normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron hydrochloride 3 mg/body administered by intravenous drip before chemotherapy (group A)
Trial: 8546476
Drug: Granisetron hydrochloride
RxNorm normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron hydrochloride 3 mg/body administered by intravenous drip before chemotherapy (group B)
Trial: 1858704
Drug: L-amino acid
RxNorm normalized name: L-α-amino-γ-methylmercaptobutyric acid
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-amino acid diets providing 40 mg leucine.kg-1.d-1
Trial: 1858704
Drug: L-amino acid
RxNorm normalized name: L-α-amino-γ-methylmercaptobutyric acid
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-amino acid diets providing 15 mg leucine.kg-1.d-1
Trial: 26261865
Drug: Long-term combination
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term combination programme (CP) comprising short-term day-hospital treatment followed by outpatient combined group and individual psychotherapy
Trial: 20499131
Drug: 2ME2 NanoCrystal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2ME2 NanoCrystal® dispersion (NCD) at 1,500 mg orally four times daily, repeated in 28 day cycles
Trial: 11896110
Drug: bioCT (CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bioCT (CT regimen followed by low-dose subcutaneous IL-2 for 8 days and IFN alpha-2b three times a week for six cycles)
Trial: 9869892
Drug: Cyclosporine (CsA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CsA) therapy
Trial: 378017
Drug: Glycopyrrolate (0.004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (0.004 mg/kg)
Trial: 30945664
Drug: MdHOXs under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MdHOXs under cold treatment
Trial: 30945664
Drug: MdHOXs under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MdHOXs under osmotic treatment
Trial: 30945664
Drug: MdHOXs under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MdHOXs under high salinity treatment
Trial: 30945664
Drug: MdHOXs under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MdHOXs under exogenous ABA treatment
Trial: 25424121
Drug: L-carnitine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (4 g/day intravenous)
Trial: 22876543
Drug: Pamidronate (PAM),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (PAM), 1 mg/kg/day over 2 days
Trial: 22876543
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZOL), 0.025-0.05 mg/kg/day over 2 days every 3-4 months
Trial: 18820247
Drug: Pre-magnesium (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-magnesium (bolus of magnesium 50 mg epidurally before induction, followed by infusion of 10 mg h(‐1) until end of surgery)
Trial: 18820247
Drug: Post-magnesium (epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-magnesium (epidural saline during the same time periods plus bolus epidural magnesium 50 mg at the end of surgery)
Trial: 10514160
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of 20 mg methylprednisolone plus lignocaine
Trial: 10514160
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice daily for two weeks
Trial: 7671364
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of digoxin (0.39 +/- 0.11 mg/day)
Trial: 25785683
Drug: Local lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local lidocaine infiltration (Group L)
Trial: 24780643
Drug: Fructose (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (60 g)
Trial: 10204835
Drug: Fructose (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (30 g)
Trial: 24780643
Drug: Sucrose (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (60 g)
Trial: 24780643
Drug: Glucose (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (60 g)
Trial: 24780643
Drug: Fructose (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (60 g) and (30 g)
Trial: 19226471
Drug: Tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine ER 4 mg once-daily for 12 weeks
Trial: 15295223
Drug: Control (hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (hepatitis B vaccine)